Asia-Pacific dPCR Market 2022-2028

Asia-Pacific dPCR Market 2022-2028

Asia-Pacific dPCR Market Size, Share & Trends Analysis Report By Product (Reagents and Consumables, Instruments and Software & services), By Application (Research Application, Clinical Application and Forensic Application) Forecast Period (2021-2028)

The Polymerase Chain Reaction (PCR) is a technique that is performed in the laboratory to amplify DNA and create its copies. It is used in biological and medical research for different applications that include- detecting the presence or absence of genes during infection, generating forensic DNA profiles from its samples and processing DNA for sequencing. A dPCR is a novel technique for the detection and quantification of nucleic acid and is an alternative to traditional real-time qPCR for absolute quantification and rare allele detection. It works by separating a DNA or cDNA sample into several individual, parallel PCR reactions. Asia-Pacific dPCR market is projected to grow at a substantial CAGR of 9.6% during the forecast period. The Asia-Pacific dPCR market was valued at $262 million in 2021 and is estimated to reach $556 million in 2028. The market for dPCR is driven by various pivotal factors such as rising demand for precision and personalized medicine, technological advancement in PCR technology, and the significance of dPCR in drug development and clinical diagnostics. Further, the growing prevalence of infectious diseases such as hepatitis B virus (HBV), malaria, and tuberculosis is projected to boost the significant adoption of dPCR technology in the region. Significant prevalence of HBV was reported in South-East Asian countries, including Thailand. According to the Taiwan Centers for Disease Control, in Taiwan, about 100-125 confirmed cases of HBV were reported to Taiwan’s National Notifiable Disease system from 2012 to 2021. This is expected to fuel the adoption of droplet digital PCR (ddPCR) in the region.

Moreover, rapidly transforming microbial research and infectious disease management scenario is further driving the market growth of Asia-Pacific dPCR technologies. Severe acute respiratory syndrome (SARS), H1N1 or swine flu, Ebola virus, and the COVID-19 pandemic caused a large number of mortalities across the Asia-Pacific region. In order to diagnose and develop a treatment for such infectious diseases, innovative technologies such as dPCR plays a pivotal role. The dPCR coupled with other new techniques such as Next-Generation Sequencing (NGS) is transforming microbial research including microbiome sequencing. The combination of increased sensitivity, and absolute quantification of microorganisms is advancing in many domains such as pathogen identification and detection, public health, epidemiology, phylogeny, characterization of the composition, and changes in microbiomes. Therefore, the growing microbiome sequencing industry will positively influence the demand for dPCR technologies. The need for innovative techniques for early detection and diagnosis of infectious diseases will create considerable demand for the dPCR technology in Asia-Pacific.

SEGMENTAL OUTLOOK

The Asia-Pacific dPCR market has been segmented based on product, and application. Based on the product, the market is segmented into reagents and consumables, instruments, and software & services. Whereas, based on the application, the Asia-Pacific dPCR market is segmented into clinical, research, and forensic applications.

On the basis of product, the reagents and consumables segment held the highest market share of around 51.0%, accounted for $133.6 million in 2021 and is estimated to reach $292.5 million in 2028. The high market share of the reagents and consumables segment is attributed to the launch of new PCR test kits for diagnosis purposes. Further, the rising number of probe-based multiplex genetic analysis procedures is also contributing to the market growth of the reagents and consumables segment. On the other hand, the instrument segment of the market is expected to grow substantially at a CAGR of 9.1% during the forecast period. The instrument segment was valued at $96.9 million in 2021 which is projected to reach $198.7 million by 2028. The segmental growth of the market is accredited to the launch of novel products by the key players operating in the market. For instance, in January 2021, QIAGEN announced the launch of next generation dPCR, with the integration of QIAGEN technologies and assets acquired from Formulatrix Inc. Whereas, in 2021, the company introduced the novel QIAseq 16S/ITS Panel UCP Multiplex PCR kit for NGS to enable one of the most accurate microbial community profilings from the complex samples.

On the basis of application, the research application segment held the major share of 52% and valued at $136.2 million in 2021 which is further anticipated to reach $287.2 million in 2028, growing at a CAGR of 9.5% during the forecast period. The segmental growth is accredited to the use of dPCR technology in various research including oncology research, genetic diseases, and stem cell research. The PCR technique is a widely used diagnostic tool in the detection of genetic diseases. The part of a gene responsible for a genetic disease makes it possible to disclose the harmful mutations, their nature, positions, and sizes. In the context of genetic diseases, the concern related to insertions and deletion arises. In these cases, the mutation is manifested by the change in the size of the gene or part of the gene. The analysis of PCR products is performed through electrophoresis, evaluation of which directly leads to the diagnosis. The detection of inversions and point mutations is more delicate which makes this technology more suitable for use in the diagnosis of genetic diseases.

REGIONAL OUTLOOK

Geographically, the Asia-Pacific dPCR market is segmented into China, Japan, South Korea, Australia, India, Taiwan, Hong Kong, Thailand and the Rest of Asia-Pacific. Among these, Chinamarket held the largest share of 25.5% and was valued at $66.9 million in 2021 which is further projected to reach $145.2 million in 2028, growing at a CAGR of 10.0% during the forecast period. The regional growth of market is attributedto technological advancement, rising geriatric population, healthcare reforms, and cohesive government regulations regarding research in the country. The increasing R&D activities for drug discovery and development in China is also estimated to contribute considerably towards the growth of the market.

Moreover, Japan accounted for the second-largest share of around 21.0% in 2021 in the Asia-Pacific dPCR market. In 2021, Japan dPCR market was valued at $55.0 million which is further estimated to reach $118.6 million in 2028, growing at a CAGR of 9.9% during the forecast period. The expansion of global players in the country is further projected to provide significant growth to the dPCR market in Japan. For instance, in May 2021, Takara Bio USA, Inc. declared that its parent company, Takara Bio Inc., has completed the construction of a new facility, the Center for Gene and Cell Therapy Processing II (CGCPII) in Shiga, Japan. The CGCPII has been operational since January 2021. The CGCPII provides an additional capacity for Good Manufacturing Practice (GMP) viral vector production, process development, aseptic filling, and quality-testing facilities, as well as room for future expansion.

KEY PLAYERS OUTLOOK

The Asia-Pacific dPCR market is characterized by the presence of several market players that are operating and providing their products and services based on dPCR technology across the region. Some of the key players of the market include Fluidigm Corp., Merck KGaA, Thermo Fisher Scientific Inc., QIAGEN N.V., and Bio-Rad Laboratories Inc., among others. These key manufacturers operating in the market are constantly investing in R&D to diversify their product range and adopting manufacturing practices that ensure improved products and quality. The presence of local manufacturers is expected to increase competition due to an increase in demand for novel products. For instance, in January 2021, QIAGEN N.V. acquired FORMULATRIX dPCR technology. In 2021, QIAGEN announced plans for the global launch of a new series of dPCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s focus on assay development and automation. Through this launch, the company aims at expanding its product and service offerings portfolio which further enables the company to strengthen its revenue stream.